Our Products

Point-of-care

With Calmark's test, a test result is obtained directly at the patient's site. By shortening the time from sampling to response, decisions on measures can be made more quickly. Phototherapy can be initiated more quickly, or the child can be sent home sooner.

Calmark's proprietary point-of-care testing platform consists of a portable instrument and a standardized test cassette.

Matrix

Compare test method

Jaundice meter
Skin screening
Laboratory testing
Laboratorytest
Calmark Neo-Bilirubin
Point-of-Care
Non-invasive
-
All ethnicities (skin colors)
-
Portable
-
Quantification 0 – 9 mg/dL – Low risk
-
Quantification 9 – 15 mg/dL – Medium risk
-
Quantification 15 – 29 mg/dL – High risk
-
Low blood volume (under 100 μL)
-
No handling of blood to extract plasma
-
No need to cover blood sample from light
-
Results within minutes
-
No interference from hemolysis (up to 2 g/L)
-
Accurate results at up to 60% hematocrit
-
No need for calibration
-
Our Products

Other products

COVID19-LDH

In addition to products for newborns, Calmark has also developed a POC test for assessing the severity of COVID-19. This is fully developed and CE marked.

By the time the pandemic hit the world in the spring of 2020, Calmark had been researching the biomarker LDH for many years. A large number of research articles were published that showed that LDH is an important piece of the puzzle for assessing the severity of Covid-19 patients.

By adapting the measurement range to adult patients, an LDH test for Covid-19 was quickly developed. The test is based on the same test cassette and instruments as the Neo products. Contact us if you want to know more about this test.

Contact us

Would you like more information?

Contact us